Catalog No.
KDD82501
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
0.31-5 μg/mL
Sensitivity
0.156 μg/ml
Precision
CV<20%
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Alternative Names
Fibatuzumab, KB-004, , CAS: 1234137-51-9
Background
Ifabotuzumab (formerly KB004) is a first-in-class therapeutic non-fucosylated IgG1 (human f-allotype) monoclonal antibody being developed by Humanigen (formerly KaloBios Pharmaceuticals) for the treatment of cancer. The drug was licensed from the Ludwig Institute for Cancer Research. The molecule contains a human antibody constant region with V-regions that are 92% identical to human germ-line sequences. Ifabotuzumab targets the ephrin type-A receptor 3 (EphA3) tyrosine kinase. In non-clinical studies, Ifabotuzumab demonstrated potent ex-vivo cell killing of EphA3+ tumor cells obtained from patients with hematologic malignancies.
For research use only. Not for human or drug use.
